Johnson & Johnson asked rival Covid-19 vaccine makers to study blood clotting risks: report

Name: SCMP Explains: What’s in a Covid-19 vaccine?
Uploaded: 2021-04-16T12:59:45.000Z
Duration: 6 min 18 s
Description: SCMP Explains: What’s in a Covid-19 vaccine?

AstraZeneca – which had been buffeted by blood clotting concerns – agreed, while Pfizer and Moderna declined, the WSJ reported

US officials had on Tuesday recommended pausing use of Johnson & Johnson’s vaccine to review cases of blood clots

Reading Time:1 minute

Why you can trust SCMP

A drummer receives the Johnson & Johnson Covid-19 vaccine in New Orleans, US. File photo: AP

Reuters

Published: 8:59pm, 16 Apr 2021Updated: 8:59pm, 16 Apr 2021

Johnson & Johnson had reached out to rival Covid-19 vaccine makers to join in an effort to study the risks of blood clots, The Wall Street Journal reported on Friday, citing people familiar with the matter.

AstraZeneca, which had been buffeted by similar blood clotting concerns for weeks, agreed, while Pfizer and Moderna executive declined, saying their vaccines appeared safe, the report said.

The US federal health agencies had on Tuesday recommended pausing use of Johnson & Johnson’s vaccine for at least a few days after six women under the age of 50 developed rare blood clots after receiving the shot.

Last week, European regulators said they were reviewing rare blood clots in four recipients of the J&J shot in the United States, after which, the Journal report said, the company began to reach out to other vaccine makers.

06:18

SCMP Explains: What’s in a Covid-19 vaccine?

Pfizer and Moderna also objected because they did not see the need to duplicate the efforts of agencies and companies that were already looking for blood clot cases and investigating the cause, according to the report.

Select Voice

Choose your listening speed

Get through articles 2x faster

1.25x

250 WPM

Slow

Average

Fast

00:0000:00

1.25x